One Big Beautiful Bill - Healthcare & Benefit Related Impacts

The massive budget reconciliation bill known as the One Big Beautiful Bill Act (OBBBA) was signed into law by President Trump on July 4, 2025. As with many such budget bills, there were various employee benefits provisions tucked into its depths, including changes for health savings accounts (HSAs), dependent care assistance programs (DCAPs), student loan payments under educational assistance programs, and qualified transportation plans. The benefit-related changes are summarized below.

Abbvie Names Magellan, EmpiRx, and CapRx in Amended Suit

Abbvie names Magellan, EmpiRx, and CapRx in amended filing targeting employer health plans use of financial assistance programs.

AbbVie is the manufacturer for the world’s most profitable drug of all time: Humira. Taking in over $200B in revenue with a >50% profit margin.

Long the thorn for employer health plans, Humira’s pre rebate cost is nearly $85k/year per patient.

Humira enjoyed monopoly status for two decades as AbbVie leveraged the court system to extend their patent protection and make deals with competitors to keep competing products off the shelves

The lawsuit brought by AbbVie targets PBMs and little known companies that exploit alternative funding arrangements for financial gain.

AbbVie, like many manufacturers offers financial aid for uninsured and underinsured patients.

Payer Matrix is one of those entities. We’ve seen contracts from PM that charge 27% of the savings for their assistance leveraging these financial aid programs.

Those savings fees rarely take into account the after rebate drug cost.

Thus, an employer can end up paying PM $22k for getting one patient their Humira for free through AbbVie’s assistance program.

PM isn’t alone in this game. Others like SHARx, ScriptSourcing, and even PBMs have gotten in the game. ScriptSourcing used to charge a 50% savings fee - I have the receipts.

Now AbbVie is crying fowl. Alleging racketeering and naming EmpiRx, Capital Rx, and Magellan PBMs as co-conspirators milking these programs and taking away funds from those in need.

These programs are opportunistic no doubt but it’s hard to sympathize with AbbVie who’s played the system better than anyone who’s come before. Remember: one drug, $200 Billion.

Now it’s off patent. Biosimilars are easily available for $800/month or less.

But Abbvie just moved the puck. Their focus is now on maximizing revenue on Skirizi and Rinvoq which come with even higher price tags.

It’s hard to argue that anyone can afford an $80k a year drug (or even $50k post rebate) when median household income is in the $50k range

So who should pay? Who can pay?

“It is amazing that people who think we cannot afford to pay for doctors, hospitals, and medication somehow think that we can afford to pay for doctors, hospitals, medication, and a government bureaucracy to administer it.”

-Dr. Thomas Sowell

Wells Fargo and PBM Hell (pt. 2)

The thing about being a fiduciary is that all responsibility and liability rests on the plan sponsor. You can hire some pretty awful vendors to manage components of your health plan but mismanagement, excess fees, self-dealing, and profiteering are the plan sponsors peril.  

Simpara Hosts 2nd Annual HEALTH x STL event at CITYPARK

On June 5, 2024 Simpara will host our 2nd annual HEALTH x STL heatlhcare innovation summit. The event is geared towards mid-sized employers in the region that are struggling to contain escalating healthcare costs.

HEALTH x STL is not just an event. It’s a movement where the brightest minds in business and health converge to share groundbreaking solutions for transforming health insurance and care.

Hear from the most innovative CEOs and Business Leaders who have eliminated deductibles, cut health spending in half, and restored meaningful wage growth to their number one asset.

Healthcare is already fixed. Join us to replicate the fixes and help transform our region.

LEARN MORE ABOUT OUR EVENT HERE: HEALTHXSTL.COM

Top